Châtillon, France, May 16, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) (the "Company"), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
The Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section (https://www.dbv- technologies.com/investor-relations/) of the Company's website: https://dbv- technologies.com/events/2024-annual-general-meeting/.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV is currently focused on investigating the
use of its proprietary technology platform, Viaskin(TM), to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through
epicutaneous immunotherapy (EPIT(TM)), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that
seeks to modify an individual's underlying allergy by re-educating the immune
system to become desensitized to allergen by leveraging the skin's immune
tolerizing properties. DBV is committed to transforming the care of food
allergic people. The Company's food allergy programs include ongoing clinical
trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age)
and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com (http://www.dbv- technologies.com/) and engage with us on X (formerly Twitter) (https://twitter.com/DBVTechnologies) and LinkedIn (https://www.linkedin.com/company/dbv-technologies/).
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv-technologies.com)
Media Contact
Aurora Krause
DBV Technologies
aurora.krause-ext@dbv-technologies.com (mailto:aurora.krause-ext@dbv- technologies.com)
Â